Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy

Poly(ADP-ribose) polymerases (PARP) are proteins responsible for DNA damage detection and signal transduction. PARP inhibitors (PARPi) are able to interact with the binding site for PARP cofactor (NAD+) and trapping PARP on the DNA. In this way, they inhibit single-strand DNA damage repair. These dr...

Full description

Bibliographic Details
Main Authors: Giorgio Valabrega, Giulia Scotto, Valentina Tuninetti, Arianna Pani, Francesco Scaglione
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:International Journal of Molecular Sciences
Subjects:
ovarian cancer
olaparib
niraparib
rucaparib
safety
efficacy
Online Access:https://www.mdpi.com/1422-0067/22/8/4203

Internet

https://www.mdpi.com/1422-0067/22/8/4203

Similar Items